BioNTech reports 36.7% response in pumitamig lung trial

BioNTech (BNTX) and Bristol Myers Squibb (BMY) reported Phase 2 trial data for pumitamig plus docetaxel in metastatic non-small cell lung cancer. The trial showed a 36.7% objective response rate and 90.0% disease control rate. Median progression-free survival was 6.9 months. Adverse events were reported in 52.0% of patients, with 18.0% grade 3 or higher. Data were presented at the European Society for Medical Oncology Congress 2026.

BioNTech (BNTX) and Bristol Myers Squibb (BMY) reported Phase 2 trial data for pumitamig plus docetaxel in advanced NSCLC. The combination showed a 36.7% objective response rate and 6.9-month median progression-free survival. The trial involved 50 patients, with responses observed across PD-L1 levels and histologies. The companies are advancing pumitamig in multiple lung cancer trials.

BioNTech SE (BNTX) reported Phase 2 data for pumitamig plus docetaxel in advanced non-small cell lung cancer (NSCLC), showing a 36.7% confirmed objective response rate and median progression-free survival of 6.9 months. The results suggest potential improvements over current standards of care, with manageable safety. BioNTech aims to advance the treatment into ongoing Phase 3 trials.

BioNTech (BNTX) and Bristol Myers Squibb (BMY) reported Phase 2 trial data showing their lung cancer drug combo, pumitamig plus docetaxel, achieved a 36.7% response rate and 6.9-month median progression-free survival in NSCLC patients who progressed after immunotherapy. The trial involved 50 patients, with 33 still on treatment. The companies are advancing multiple Phase 3 trials for pumitamig in various lung cancer settings.

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

Bristol Myers Squibb reported a patient death in a Phase 1 trial for its CAR-T therapy targeting multiple sclerosis. The patient had pre-existing complications and died from septic pneumonia. The company noted this may impact the therapy's safety assessment. The incident raises concerns about CAR-T therapy's safety and regulatory challenges in autoimmune treatments.